NCT05040789撤回3 期
A Randomized, Observer-Blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18-49 Years of Age
Medicago4 个研究点 分布在 1 个国家开始时间: 2021年11月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 试验地点
- 4
- 主要终点
- GMTs of the three vaccine lots
研究概览
简要总结
This Phase 3 study is intended to assess clinical lot-to-lot consistency by evaluating and comparing the immunogenicity of three consecutively manufactured lots of Coronavirus-like Particle (CoVLP).
详细描述
This is a randomized, observer-blinded, multicenter, Phase 3 lot-to-lot consistency study in approximately 900 healthy seronegative adults 18-49 years of age after the administration of two doses of CoVLP (3.75 ug) adjuvanted with AS03 (referred to as "CoVLP formulation").
Subjects who are seronegative for SARS-CoV-2 antibodies will be randomized in a 1:1:1 ratio to receive one of three lots of the CoVLP formulation. Subjects will receive two intramuscular injections 21 days apart. The same lot will be used for both IM injections in each subject. Safety and immunogenicity assessments will be performed. Subjects will participate in this study for approximately 49 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects must be 18 - 49 years of age at screening visit.
- •Subjects must have a body mass index < 35 kg/m2 at screening visit.
- •Subjects must be in good general health prior to study participation. Note: Subjects with a pre-existing chronic disease will be allowed to participate if the disease is stable and the condition is unlikely to confound the results of the study or pose additional risk to the subject.
- •Female subjects of childbearing potential must have a negative urine pregnancy test result prior to vaccination.
- •Female subjects of childbearing potential must use a highly effective method of contraception starting one month prior to vaccination, continuing until the end of the study, and must not plan to become pregnant for at least one month after her last study vaccination.
排除标准
- •Significant acute or chronic, uncontrolled medical or neuropsychiatric illness.
- •Any confirmed or suspected current immunosuppressive condition or immunodeficiency, including cancer, human immunodeficiency virus (HIV), hepatitis B or C infection (subjects with a history of cured hepatitis B or C infection without any signs of immunodeficiency at present time are allowed).
- •Current autoimmune disease (such as rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis).
- •Administration of any medication or treatment that may alter the vaccine immune responses, such as:
- •Systemic glucocorticoids at a dose exceeding 10 mg of prednisone (or equivalent) per day for more than seven consecutive days or for 10 or more days in total, within one month prior to the Vaccination visit (Visit 2). Inhaled, nasal, ophthalmic, dermatological, and other topical glucocorticoids are permitted.
- •Cytotoxic, antineoplastic, or immunosuppressant drugs - within 36 months prior to Vaccination (Visit 2).
- •Any immunoglobulin preparations or blood products, blood transfusion - within 6 months prior to Vaccination (Visit 2).
- •Administration of any vaccine within 14 days prior to Vaccination (Visit 2); planned administration of any vaccine during the study (up to Day 28 of the study).
- •Administration of any other SARS-CoV-2 / COVID-19, or other experimental coronavirus vaccine at any time prior to or during the study.
- •History of virologically-confirmed COVID-
- •Use of any investigational or non-registered product within 30 days or 5 half-lives, whichever is longer, prior to Vaccination (Visit 2) or planned use during the study period.
- •Have a rash, dermatological condition, tattoos, muscle mass, or any other abnormalities at injection site that may interfere with injection site reaction rating.
- •Use of any prescription antiviral drugs with the intention of COVID-19 prophylaxis, including those that are thought to be effective for prevention of COVID-19 but have not been licensed for this indication, within one month prior to Vaccination (Visit 2).
- •History of a serious allergic response to any of the constituents of CoVLP including AS
- •History of a documented anaphylactic reactions to plants or plant components (including tobacco, fruits and nuts).
- •Personal or family (first-degree relatives) history of narcolepsy.
- •Subjects with a history of Guillain-Barré Syndrome.
- •Any female subject who has a positive or doubtful pregnancy test result prior to vaccination or who is lactating.
结局指标
主要结局
GMTs of the three vaccine lots
时间窗: Up to Day 42 (21 days after the second vaccination)
Nab response induced against the SARS-CoV-2 virus on Day 42 will be analyzed using GMTs of the three vaccine lots on Day 42 adjusted for Day 0 GMTs.
次要结局
- Unsolicited adverse events(21 days following each vaccination)
- Immediate adverse events(30 minutes after each vaccine administration)
- Solicited adverse events(Seven days following each vaccination)
- SC rates(21 days after the second vaccination)
- Other adverse events(Up to 21 days following each vaccine administration)
- GMFRs(21 days after the second vaccination)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy AdultsVirus DiseasesRNA Virus InfectionsRespiratory Tract InfectionsRespiratory Tract DiseaseInfluenzaNCT03321968Medicago1,202
已完成
3 期
VELOCITY: An Anthrax Vaccine Clinical StudyAnthraxNCT03877926Emergent BioSolutions3,689
尚未招募
3 期
A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT06492941CSPC ZhongQi Pharmaceutical Technology Co., Ltd.142
已完成
3 期
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese PatientsParkinsonian SyndromeParkinson Disease(PD)Multiple System Atrophy (MSA)Progressive Supranuclear Palsy (PSP)Essential TremorNCT04193527GE Healthcare172
进行中（未招募）
3 期
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCSquamous Non Small Cell Lung CancerNCT04033354Shanghai Henlius Biotech537